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Summary The present studies were initiated to quantitate the oxygen dependence ofbioreductive metabolism-
induced binding of EF5, a pentafluorinated derivative of the 2-nitroimidazole, etanidazole. Two different
assays were compared: first, radioactive drug incorporation into cell lysates, which provides a direct measure
of drug metabolism or uptake; second, monoclonal antibody detection of cellular macromolecular adducts of
EF5 after whole cell permeabilisation and fixing. The antibodies (a single clone designated ELK3-51) were
conjugated with the fluorescent dye Cy3, with fluorescence determined by fluorescence microscopy and flow
cytometry. For the two cell lines tested (V79 Chinese hamster fibroblasts and 9L rat glioma), the oxygen
dependence of binding was found to be the same for the two techniques. Using the antibody binding
technique, the fluorescence signal was highly reproducible between experiments, resistant to light or chemical
bleaching and stable over time following cell or tissue staining. Flow cytometric analysis of cells from rat 9L
tumours treated with EF5 in vivo or in vitro showed a distribution of fluorescent signal which was very
compatible, on both a relative and absolute basis, with the in vitro results. Our results indicate that
immunofluorescent techniques provide a quantitative assay for bioreductive drug adducts, and therefore may
be able to measure the absolute oxygen concentration distribution in cell populations and tissues of interest.
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The bioreductive activation of nitroheterocyclic drugs causes
the formation of adducts to cellular macromolecules. We
refer to this process as binding. Binding is maximal in the
absence of oxygen, and is markedly inhibited as the concen-
tration of oxygen increases; thus, detection of the bound
adducts provides an assay signal which increases as the
oxygen concentration decreases (Varghese et al., 1976; Chap-
man, 1979; Koch et al., 1984). Drug binding is therefore an
assay for hypoxia, and has been measured in a number of
ways: radioactive drug binding allows detection by several
different types of radioactivity assays (Varghese et al., 1976;
Chapman et al., 1983; Urtasun et al., 1985; Rasey et al.,
1987; Parliament et al., 1992), fluorine-containing drug bin-
ding allows detection by magnetic resonance spectroscopy or
imaging (Raleigh et al., 1984) and antigenic properties of the
drug adducts allow secondary detection by antibodies
(Raleigh et al., 1987; Hodgkiss et al., 1991; Lord et al., 1993).
The last technique has potential for a very high degree of
spatial resolution, and allows assays such as the microscopic
distribution of adducts in tissue sections or flow cytometric
analysis of individual cells (Hodgkiss et al., 1991). Although
both polyclonal and monoclonal antibodies have been
developed against various adducts of 2-nitroimidazole drugs
(Raleigh et al., 1987; Hodgkiss et al., 1991; Lord et al., 1993),
it has not been shown that this technique can provide a
quantitative assessment of the number of adducts present. In
fact, one might expect this not to be the case since the
adducts appear to be formed throughout the entire intracellu-
lar environment (Lord et al., 1993), probably at cysteine
residues ofintracellular proteins (Raleigh and Koch, 1990). It
is known that the intracellular concentration of adducts can
easily be several hundred micromolar - e.g. after a non-toxic
drug exposure of 1I00 M for 3 h in nitrogen (Koch, 1990).
This concentration corresponds to several hundred million
adducts per cell, possibly in very diverse physical-chemical
environments. The detection of antigen in such conditions
has not previously been studied. Even if one assumed com-
plete access of antibodies to the intracellular environment
(e.g. after fixation and permeabilisation) simple calculations
suggest that there might not be 'room' to detect all antigen.
An antibody concentration of 500 t5M would be 7.5% protein
(by weight); the preexisting protein content of cells or tissues
is typically approximately 20%.
After antibodies have bound to their target antigen, the
quantitative detection of the antibodies poses an additional
challenge. Use of secondary antibodies or proteins (like
avidin) coupled to enzymes causes problems with steric access
to the initial adduct sites, prevention of non-specific binding,
etc. One is then faced with the necessity of quantitating the
amount of product formed (e.g. in enzyme-based assays, any
resulting image would have to be analysed by measuring
chromophore concentration via absorption measurements).
In addition, the use of secondary proteins requires the
optimisation of two separate protein binding steps (primary
antibody and secondary detection molecule) and the binding
of both must be stable during the enzyme reaction. Use of a
second protein would only exacerbate the above described
protein concentration problems. For these reasons, we have
adopted the approach of using a single protein detection
system consisting of a monoclonal antibody to the drug
adduct, with detection based on the fluorescence of a
fluorophore which is chemically coupled to the antibody. In
spite of the poor reputation of fluorescence detection as a
quantitative technique, this approach had the advantages of:
(a) minimising the size of the detecting molecules (since
fluorophors have a much lower molecular weight than secon-
dary proteins); (b) allowing the optimisation of binding, in-
cluding prevention of non-specific binding of a single protein;
(c) providing a detection technique which should give a signal
directly proportional to the amount of antibody present and
(d) allowing the use of flow cytometric analysis techniques to
assay the distribution of signal within individual cells of a
heterogeneous population.
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The 'signal' from an ideal hypoxia detector should have
the properties of a consistent maximum signal in the absence
of oxygen and the same oxygen dependence of decreasing
signal from cell-to-cell or tissue-to-tissue. Much previous
work, using cell lines as well as normal and tumour tissue
cubes derived from animals and humans, has demonstrated
that binding of drugs such as misonidazole fails to demon-
strate the ideal properties listed above (Koch, 1990; Koch et
al., 1993; Franko and Koch, 1984; Franko et al., 1987; Cobb
et al., 1989, 1992). Thus, many different cells and tissues have
greatly differing absolute and oxygen-dependent binding of
misonidazole. The reasons for this variability in cells are
unclear. In contrast, we have found very consistent binding
efficiencies for all 2-nitroimidazoles studied using model
systems and radiochemical reduction techniques (Raleigh and
Koch, 1990). However, these model studies have only been
done at very low oxygen concentrations. It seems quite poss-
ible however that cell and tissue differences in binding of
drugs such as misonidazole may reflect differences in the
concentration or type of nitroreductase present (Cobb et al.,
1992; Workman, 1992; Joseph et al., 1994). As in the radia-
tion chemical model, little is known about the binding subs-
trates and oxygen dependence of suggested enzymatic nitro-
reductases. Alternatively, the type, chemical environment or
concentration of suitable target binding sites may vary from
cell to cell. We showed a tremendous enhancement (100-fold)
in binding efficiency in the radiochemical model system by
including protein thiols as binding substrates (Raleigh and
Koch, 1990). During previous investigations we found two
tissue culture cell lines which demonstrated the variability of
misonidazole binding to a near maximal extent - WNRE, a
subline of V79 Chinese hamster fibroblasts and 9L, a line
derived from a rat glioma (Koch, 1990).
We have shown that binding of etanidazole conforms
much more closely to the ideal hypoxia detector described
above (Koch, 1990; Koch et al., 1993). However, etanidazole
is very polar, and tends to form most adducts with acid-
soluble cellular molecules (Koch, 1990). High polarity would
also prevent etanidazole from distributing evenly to all tis-
sues in animals. Additionally, it does not have a suitable
detection scheme. Thus, we have provided an initial charact-
erisation of a pentafluorinated derivative ofetanidazole [EF5;
2-(2-nitro- 1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-
acetamide] as a hypoxia detector (Lord et al., 1993). Mono-
clonal antibodies which recognise cellular adducts ofthe drug
were found to be highly specific (Lord et al., 1993). The
present study continues this characterisation using the same
two cell lines (WNRE and 9L) which previously had been
shown to have the most variability in oxygen dependent
binding of misonidazole, and using a new monoclonal
antibody, ELK3-51, with significantly higher affinity allowing
the use of much lower drug concentrations.
Materials and methods
Drug synthesis
A pentafluorinated derivative [2-(2-nitro-lH-imidazol-l-yl)-
N-(2,2,3,3,3-pentafluoropropyl)acetamide] of etanidazole, in
unlabelled and labelled form ("'C-2 position; 43ILCi mg' )
was synthesised by Dr M Tracy and colleagues at Stanford
Research International, Palo Alto, CA, USA and is referred
to as EF5 in this manuscript.
Preparation ofcells in tissue culture at defined oxygen
conditions
The cells used were derived from 9L rat glioma (Wong et al.,
1991; Evans and Koch, 1994) or the WNRE subline of V79
Chinese hamster fibroblasts (cells obtained in 1981 from Dr
JD Chapman, presently of Fox Chase Cancer Center, Phila-
delphia, PA, USA). The cells were thawed from frozen stock
two (WNRE) and four (9L) times per year. Tests were made
routinely to ensure that the cultures were free from myco-
plasma and other contaminants. The cells were cultured
(37°C, 95% air + 5% carbon dioxide, 100% relative
humidity) in the exponential phase of growth by transfers at
roughly 3.5 day intervals using Eagle's minimal essential
medium containing 13% (v/v) of either newborn calf serum
(9L) or fetal calf serum (WNRE). Penicillin and streptomycin
were also routinely included (all culture solutions from Sigma
or Fisher). On the day preceding an experiment, cells were
trypsinised and plated onto glass Petri dishes (50 mm
diameter; approximately 250 000 cells confined to the central
area of the dish followed by overnight incubation at 37°C;
Koch, 1984). The dishes were removed from the incubator,
cooled to 0-4°C, and their medium was replaced with fresh
medium (with or without EF5 as required), first as a rinse
(1 ml) which was simply aspirated and then as the actual
medium used for the experiment (also 1 ml). Dishes were
placed in leakproof aluminium chambers which were con-
nected to a manifold allowing the gas phase of the chambers
to be exchanged for the desired oxygen concentration in a
series of gas exchanges taking approximately 30 min. The
confinement of cells to the central area of the dish, and the
use of a small volume of medium allows very rapid equili-
bration of the gas and liquid phase to improve the control of
oxygen concentration (Koch, 1984). After gas exchange, the
chambers were immersed in a 37°C water bath, for rapid
warming, dried, and transferred to a 37°C warm room. To
prevent minor gradients of oxygen or other nutrients or
metabolites, the chambers were also shaken gently (1 Hz,
2.5 cm stroke).
In some experiments 9L cells were obtained directly from
tumours (see accompanying manuscript). They were dis-
sociated using previously described methods (Howell and
Koch, 1980; Evans and Koch, 1994).
EF5 binding: radioactivity assay
Binding of radioactive nitroheterocyclics after incubation
under defined experimental conditions was assessed as des-
cribed previously (Koch et al., 1984, 1993). Briefly, the dishes
were removed from the chambers, then medium containing
EF5 was replaced with non-drug-containing medium in a
series of rinses, the cells were removed from the dishes with
trypsin, trypsin was inactivated with serum-containing med-
ium, and the cell number was determined via a particle
counter (Coulter). The cells were lysed with 5% trich-
loroacetic acid and radioactive counts in the acid-soluble vs
acid-precipitable component were determined with standard
liquid scintillation techniques using a Packard 1900 TR
counter. The uniformity of the cell samples required no
corrections for quenching with 14C- label. The scintillation
fluid was Ecolite (ICN). EF5 binding is equally distributed
between acid-soluble and -insoluble fractions under all condi-
tions studied (data not shown) so the total counts were
simply combined in the figures.
Preparation ofmonoclonal antibodies
Monoclonal antibodies were made against radiochemically
produced adducts of EF5 and thiol-containing proteins as
described previously (Lord et al., 1993). The antibodies used
in the present study are derived from a single new clone and
are designated as ELK3-51. They have a substantially higher
affinity to EF5 and EF5 protein adducts than the antibodies
described in our original study (ELK2-4; Lord et al., 1993)
(data not shown). The monoclonal antibodies were con-
jugated with the fluorescent dye, Cy3 (Southwick et al.,
1990). This dye is available in a form which reacts with
secondary protein amines (Biological Detection Systems,
Pittsburgh, PA, USA). The dye-protein ratio was about 4.
EFS Binding: Fluorescence Assay
Cells were treated as above but radioactive EF5 was not
required. After incubation in nitrogen or various levels of
oxygen, the dishes were removed from the chambers and cells
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were removed as above. They were centrifuged out of the
inactivated trypsin solution and fixed for 1 h in ice-cold
Dulbecco's phosphate-buffered saline (PBS) containing fresh-
ly dissolved paraformaldehyde (4%, Sigma P-6148). The pH
was adjusted to 7.1-7.4 by the addition of sodium hydroxide
(about 400 tlI of IN sodium hydroxide for 200 ml of parafor-
maldehyde solution). The cells were then rinsed twice in PBS.
Non-specific binding was blocked by addition of PBS con-
taining 0.3% Tween 20 (Sigma P-2287), 1.5% albumin, 20%
non-fat milk and 5% mouse serum (Jackson Laboratories,
015-000-001) (4°C, overnight). The blocking solution was
then removed, the cells rinsed with PBS and antibody added
at a concentration of 751agml-' for 6h at 4°C. Extensive
rinsing (three changes of PBS with 0.3% Tween 20 for
40 min each) was followed by storage of cells in PBS with
1% paraformaldehyde. The exchange of each solution was
accomplished by centrifuging cells at 1200 r.p.m. for 12 min,
aspirating the supernatant and resuspending in the next solu-
tion. Typically, 1-2 million cells were treated in a 2 ml
polypropylene centrifuge tube. The cells were blocked and
stained in a 75 pl volume, but rinses and fixation used 1 ml
volumes. During all but the centrifugation steps cells were
maintained in suspension by an oscillatory tipping device
(Thermolyne SpeciMix). Stability of the antigen and bound
antibody was enhanced by the addition of 1% parafor-
maldehyde at the end of the procedure. This did not decrease
the apparent fluorescence intensity. Cells were either dried
onto microscope slides and photographed or analysed by
flow cytometry.
The Flow Cytometry Facility at the Cancer Center,
University of Pennsylvania, has a FACstar Plus instrument
(Becton Dickinson, Mountain View, CA, USA) equipped
with a water-cooled 200 mW argon laser. Although the Cy3
dye is optimally excited at 565 nm, the highest available
wavelength was 514 nm. Reproducibility of this instrument
was excellent on a week to week basis, based on the signal
from calibration beads (tetramethyl rhodamine; Flow Cyto-
metry Standards Corporation, NC, USA). A constant vol-
tage of 450 was used for the photodetector tubes.
Tumour tissue sections (see accompanying manuscript)
Tumour sections were cut at 14 jsm thickness using a Microm
HM 505 N cryostat and collected onto poly-L-lysine-coated
microscope slides. Staining of the tissue sections was the
same as for the whole cells, except that rinses were done by
simply moving each slide from container to container.
Fluorescent cells or tissues were photographed using a
Nikon epifluorescent microscope. In order to take full advan-
tage of the large dynamic range of the drug-antibody com-
bination with fluorescence photography of cells or tissue
sections, it was important to pay attention to all sources of
(stray) light in the photographic process. An unexpected
problem was 'brought to light' in our continuing attempts to
use a sensitive digital camera (Xillix, Vancouver, British Col-
umbia, Canada) rather than the intermediate analogue film.
It was found that the microscope's band-pass excitation filter
allowed a very substantial, infrared (IR) leakage from the
mercury lamp; emission filters are usually 'high pass', and
even if of the band-pass type, may not specifically exclude IR
light. It was easy to identify the IR leakage because the
digital camera is very sensitive to such wavelengths, and was
clearly responding to something which appeared invisible to
human vision. Nevertheless, IR leakage is also very impor-
tant for conventional film photography. First, it interferes
dramatically with the automatic exposure indicator (Nikon,
UFX-IIa) which, like the digital camera, is also a solid-state
device. Second and more importantly however, the IR
leakage can very substantially degrade the image, even using
conventional film.
The solution to this problem was to include a multidecade
IR cut-off filter (type XF-86; Omega Optical, Brattleboro,
VT, USA) in the light path of the emission optics. A con-
venient location in our microscope was at the base of the
camera tube. This type of filter has almost no absorption in
the visible spectrum. However, with the IR filter in place, the
automatic exposure meter now accurately monitors the actual
amount of visible light. In addition to the exposure problem,
the IR leakage caused general fogging of the slides. Thus,
before the addition of the filter, it was always possible to
visualise the separation between adjacent 36 mm fields of an
uncut film, even if there was no slide in the field of view.
However, it is now often difficult to cut the film because the
lowest exposed regions are as dark as the unexposed film
between fields.
Results
Under conditions of extreme hypoxia and over a drug con-
centration range of 4-100AM, the 9L cell line showed a
2-3-fold increased rate of '4C-labelled EF5 binding com-
pared with the WNRE cell line (Figure 1). This result is
consistent with a nearly identical oxygen dependence of rate
of binding for the two cell lines, considering the 3-fold larger
volume of the 9L cell (determined using a Coulter Counter,
protein content per cell, or cellular-space measurements;
Koch et al., 1989).
Representative data using the antibody detection technique
and flow cytometric analysis indicated a contrast ratio of at
least 50 between cells incubated in nitrogen vs 4% oxygen
(Figure 2). The low level of fluorescence seen at relatively
high oxygen levels is caused both by low levels of actual drug
adducts (see Figure 1) and residual non-specific binding of
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Figure 1 Radioactive drug binding to WNRE and 9L cells as a
function of the oxygen concentration in the gas phase of the
chambers containing glass dishes with inoculated cells. Open
symbols are for 411M drug and closed symbols 1001lM drug; (O
and *), WNRE cells; (O and *), 9L cells. Each point represents
the average rate of drug uptake, which we have found to be
linear with time.
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Figure 2 Representative plots of number of particles (linear
scale) vs fluorescence intensity (four decade logarithmic scale) for
9L cells incubated with 100jAM EF5 for 3 h at the indicated
oxygen partial pressures, then fixed and stained with Cy3-
conjugated anti-EF5 monoclonal antibodies (ELK3-51).
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the ELK3-51 antibody (see curve for cells incubated without
drug). These conclusions arise from the observations that
antibody-stained, non-drug treated cells always had a lower
level of fluorescence than EF5-treated cells in air, but that
cells not stained by the antibody (whether drug-treated or
not) had a still lower level of fluorescence (data not shown).
The oxygen dependence of binding was the same using
assays based on either radioactive drug uptake or antibody
staining (Figures 3 and 4). For measurement of binding of
14C-labelled EF5 cells were lysed and analysed after about
30 min of rinsing following exposure to drug; however, the
antibody measurement technique required extensive time
after drug exposure for fixation, blocking, staining and rins-
ing in solutions containing a mild detergent (0.3% Tween 20).
Therefore, it was of interest to measure the loss of radio-
active drug metabolites under the same conditions used to
effect the antibody staining. We found that more than 50%
of the acid precipitable radioactive counts remained with the
cells during the antibody staining procedure, while most of
the acid soluble counts were lost (data not shown). Thus,
although clearly some antigen is lost, this loss appears to be
very reproducible and may be associated with drug binding
to relatively low molecular weight molecules (work in pro-
gress).
Representative flow cytometry of cells obtained from a
tumour treated in vivo with EF5 (Figure 5) showed a range
ofbinding which was very similar, on an absolute basis, to the
range observed for cells handled entirely in vitro, if allowance
is made for the somewhat smaller cells from tumours and the
pharmacological decay of drug in vivo. One difference was
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observed however. There was a component of small particles
(based on the dot plot of forward vs side scatter - see
accompanying manuscript) with levels of fluorescence even
lower than unstained cells in vitro (i.e. particles with
fluorescence levels less than 10).
To determine the characteristics of this cell population we
disaggregated cells from a tumour in an untreated animal
and exposed the resulting cells to 100ylM EF5 under various
oxygen conditions in vitro. This component did not show an
increase in fluorescence under conditions of incubation which
would normally enhance binding (i.e. decreasing levels of
oxygen with EF5 present), even though the larger cells bound
EF5 with the same kinetic characteristics as tissue culture
cells (Figure 6). Thus, we believe that this component con-
tains debris and metabolically dead cells.
The presence of this component of particles from disagg-
regated tumours would explain the larger range of fluor-
escence intensities found for disaggregated tumour cells
treated in vivo with EF5 than we have found for tissue
culture cells. Additional factors involve the much larger size
range of cells from tumours, including red cells and host
immune cells. Some of these host cells may be associated
with the blood in the tumour at the time of disaggregation,
rather than the tumour itself.
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Figure 3 Direct comparison of relative median fluorescence
intensity (-) and radioactive drug uptake (0) for WNRE cells
incubated with 1I00jM EF5 for 3 h at the indicated oxygen
partial pressures. Data were normalised to 0.6 under conditions
of very low oxygen to move points from axis. The lowest oxygen
levels plotted are about 0.01%, which is the maximwn oxygen in
the gas phase of the chambers after the 3 h incubation period.
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Figure 5 Flow cytometric analysis of cells from 9L tumour
(tumour 'A' in accompanying manuscript) incubated in vivo, with
100ILM EF5 for 3 h, then fixed, stained and analysed as in Figure
2.
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Figure 4 Direct comparison of relative median fluorescence
intensity (U) and radioactive drug uptake (0) for 9L cells
incubated with 100 JiM EF5 for 3 h at the indicated oxygen
partial pressures. Data normalised as in Figure 3.
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Figure 6 Flow cytometric analysis of cells from 9L tumour,
treated in vitro with 1I00 1LM EF5 at various oxygen partial pres-
sures, then fixed, stained and analysed as in Figure 2. Note that
one population of cells behaves in nearly identical fashion to cells
in tissue culture, but a second population remains at very low
fluorescence irrespective of drug and oxygen concentration.
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1Discussion
The uniform binding properties of EF5 in cell lines prev-
iously shown to exhibit marked heterogeneity of binding of
misonidazole suggests that this new drug represents a sub-
stantial improvement in the elimination of variability in the
oxygen- and cell line-dependent binding by 2-nitroimidazoles
(Koch, 1990). Thus, one of the most serious problems with
the 2-nitroimidazole binding technique for measuring hyp-
oxia may be eliminated by a suitable choice of compounds.
Furthermore, the range of fluorescence intensities at the high
values consistent with conditions of very low oxygen are the
same on an absolute basis for cells treated for 3 h with
100ILM EF5 either in vitro (present manuscript) or in vivo (see
also accompanying manuscript). This may allow a direct
estimation of the range of oxygen concentrations, averaged
over the time of drug exposure, for individual cells compris-
ing a tumour.
The stability of the fluorescence signal using the Cy3-
labelled ELK3-51 antibody has been found to be excellent, as
long as the stained cells are stored in a dilute (1%) parafor-
maldehyde solution. No degradation in fluorescent signal has
been found with storage of stained cells for at least 3 weeks
at a temperature of 4°C (data not shown). Previous studies,
where the cells were either held in PBS before Ab staining
and flow cytometric analysis, or stained and then held in PBS
for flow cytometric analysis, showed a slow but continual
loss of antigen and/or antibody (data not shown). Storage of
cells in PBS with Tween 20 caused a sharp loss in signal after
3-5 days. The signal from tissue sections stained with this
antibody and fluorochrome is also exceptionally stable when
the slides were stored in cold PBS with 1% paraform-
aldehyde. We have observed reasonably stable fluorescence
over many weeks of storage (based on the photometer
associated with the Nikon microscope). The fixative does not
have any apparent negative effects on the subsequent analysis
of fluorescence. Indeed, this relatively new dye (Southwick et
al., 1990) appears to be remarkably free from problems of
fading or photobleaching when used in the manner described
in this report. Before using simple storage in PBS with dilute
fixative we had tried many remedies for preservation of
fluorescence, including the use of singlet oxygen or radical
scavengers (Valnes and Brandtzaeg, 1985) and various
aqueous and non-aqueous coverslip mounting media. Use of
mounting media was particularly problema¶ic, sometimes
leading to loss of localisation of the antibody and suscep-
tibility to photobleaching. If coverslips are required (for high
magnification) we have found that it is best to simply mount
the coverslip in the same PBS-paraformaldehyde. Such slides
must, of course, be treated extremely carefully to prevent
damage to the section and dessication can cause problems
unless the slides are stored at 100% relative humidity.
The dynamic range of binding by EF5, as measured by
radioactive drug uptake, is very large (factor of at least 50
between nitrogen and air). Thus it is important that the drug
adduct-detecting antibodies have very high sensitivity (affin-
ity) and specificity. Clearly, this is the case for ELK3-51,
since binding, as detected by flow cytometric analysis, has the
same dynamic range and oxygen dependence as does the
radioactivity assay. Both assays are sensitive enough to detect
the difference in signal between aerobic cells with 100 IM
drug vs aerobic cells without 100 gM drug. However, the
immunological method is able to do so on an individual cell
basis whereas the radioactivity measurement typically aver-
ages the total incorporation of several hundred thousand
cells.
For the present limited number of cell lines tested, the
oxygen-dependent inhibition of EF5 binding is consistent
enough to accurately monitor oxygen over the entire
physiological range. In particular, the rate of binding is very
similar, on an absolute basis, in the two cell lines (WNRE
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and 9L) previously shown to have the greatest variability
with misonidazole binding. The WNRE line demonstrated
half-order kinetics (in other words the rate of binding in-
creased as the square root of misonidazole concentration),
and was very sensitive to extremely low oxygen concentra-
tions (Chapman et al., 1983; Koch et al., 1984). The 9L line
demonstrated first-order kinetics (rate of binding increased
directly with misonidazole concentration) and was not very
sensitive to very low oxygen levels (Koch, 1990). These very
low oxygen concentrations (below 0.1% oxygen) do not
modify the radiation response, so variations in binding in this
region of oxygen concentration can produce a highly inac-
curate estimate of the radiation resistance. Indeed, extremely
hypoxic cells may not be viable in vivo, so high binding for
extremely vs moderately hypoxic cells is undesirable. The
details of this relationship remain to be determined however,
and may in fact be different for different tumours.
Our current research is directed at testing the hypothesis
that the assay of binding of EF5 can predict for the hypoxic
fraction, and hence radiation resistance, of individual
tumours. The results presented here show that this may be
possible using relatively simple flow cytometric techniques.
For cells disaggregated from 9L tumours, both the relative
and absolute amount of binding were similar to values
obtained in vitro, if we consider that the cells from tumours
were somewhat smaller and had a smaller overall drug
exposure (caused by drug distribution and half-life effects).
Both factors contribute a factor of about 0.5. Furthermore,
the tissue sections from the same tumour showed large
regions of very bright binding with varying patterns (see
accompanying manuscript). Some but not all of these pat-
terns were consistent with the capillary diffusion model of
Thomlinson and Gray (1955). The large dynamic range of
the drug-antibody detection scheme shows that there is a
continuous distribution of binding throughout the tumour.
Although this is what should be expected of the oxygen
distribution, it is more common to think of tumours as
having an 'aerobic' and 'hypoxic' fraction. Other patterns of
drug binding have not previously been observed, namely
large fields with high to very high binding throughout. This is
not unique to the 9L tumours grown as epigastric tissue
isolates, and similar results have been found in subcutaneous
9L tumours as well as FSall tumours in mice (Evans et al.,
1994; Koch et al., 1995).
The present results suggest that binding of EF5 can be
assessed quantitatively using immunofluorescent techniques;
thus it will be possible to test for inter- and intra-tumour
heterogeneity of bound EF5 using simple biopsy techniques
and flow cytometric analysis. The capability of using flow
cytometry techniques will then allow the simultaneous assay
of many other important tumour/host cell properties. In
addition, the use of fluorescence immunohistochemical tech-
niques allows for the very rapid analysis of the distribution
of EF5 binding in any normal/tumour tissue of interest.
Quantitation of the two-dimensional change in fluorescence
intensity appears very possible, requiring only a reliable light
source and/or fluorescence standard coupled with the digital
analysis of fluorescence intensity. Current work is moving
from the use of a slide-film intermediate to direct digital
image acquisition (Xillix Technologies, Vancouver, British
Columbia, Canada). Thus, we anticipate that the direct test
of the above-mentioned hypothesis is within reach.
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